Authier François-Jérôme
Centre de référence des maladies neuromusculaires Garches-Necker-Mondor-Hendaye, groupe hospitalier Albert-Chenevier-Henri-Mondor AP-HP 94010 Créteil, France.
Rev Prat. 2008 Dec 31;58(20):2253-60.
Dysimmunes and inflammatory myopathies (DIM) are divided in four groups, on the grounds of clinical and histopathological criteria: dermatomyositis, polymyositis, inclusion body myositis and autoimmune necrotizing myopathy. They may present as unique condition (primary DIM), or in association with cancer (paraneoplastic DIM) or connective tissue disease (overlap syndrome). All of them but inclusion body myositis usually respond to immunomodulatory therapy, including steroids, immunosuppressive drugs, and intravenous immunglobulins. However, most often they are chronic diseases with relapses and therapeutic failure.
免疫失调性和炎性肌病(DIM)根据临床和组织病理学标准分为四类:皮肌炎、多发性肌炎、包涵体肌炎和自身免疫性坏死性肌病。它们可能表现为单一病症(原发性DIM),或与癌症相关(副肿瘤性DIM)或结缔组织病(重叠综合征)。除包涵体肌炎外,所有这些疾病通常对免疫调节治疗有反应,包括类固醇、免疫抑制药物和静脉注射免疫球蛋白。然而,它们大多是伴有复发和治疗失败的慢性疾病。